Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan

Hsi Che Liu, Ming Chung Kuo, Kang Hsi Wu, Tsai Yun Chen, Jiann Shiuh Chen, Ming Chung Wang, Tung Liang Lin, Young Sen Yang, Ming Chun Ma, Po Nan Wang, Jiunn Ming Sheen, Shih Chung Wang, Shih Hsiang Chen, Tang Her Jaing, Chao Neng Cheng, Ting Chi Yeh, Tung Huei Lin, Lee Yung Shih*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

1 Scopus citations

Abstract

BACKGROUND: The direct comparison of molecular responses of front-line imatinib (IM) monitored at the same laboratory between children and adults with chronic phase (CP) of chronic myeloid leukaemia (CML) had not been reported. In this multicenter study, we compared the landmark molecular responses and outcomes of paediatric and adult CML-CP cohorts treated with front-line IM in whom the BCR::ABL1 transcript levels were monitored at the same accredited laboratory in Taiwan.

METHODS: Between June 2004 and July 2020, 55 newly diagnosed paediatric and 782 adult CML-CP patients, with molecular diagnosis and monitoring at the same reference laboratory in Taiwan, were enrolled. The criteria of 2020 European LeukemiaNet were applied to evaluate the molecular responses.

RESULTS: By year 5, the cumulative incidences of IS <1%, MMR, MR 4.0 and MR 4.5 of paediatric patients were all significantly lower than those of adult patients (58 vs 75%, 48 vs 66%, 25 vs 44%, 16 vs 34%, respectively). The 10-year progression-free survival (PFS) (90%) and overall survival (OS) (94%) of paediatric patients did not differ from those (92%) of adult patients.

CONCLUSIONS: We demonstrated the paediatric cohort had slower molecular responses to front-line IM and similar outcomes in 10-year PFS and OS in real-world practice.

Original languageEnglish
Pages (from-to)1294-1300
Number of pages7
JournalBritish Journal of Cancer
Volume128
Issue number7
DOIs
StatePublished - 30 03 2023

Bibliographical note

© 2023. The Author(s), under exclusive licence to Springer Nature Limited.

Keywords

  • Adult
  • Humans
  • Child
  • Imatinib Mesylate/therapeutic use
  • Antineoplastic Agents/therapeutic use
  • Taiwan/epidemiology
  • Protein Kinase Inhibitors/therapeutic use
  • Treatment Outcome
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
  • Fusion Proteins, bcr-abl/genetics

Fingerprint

Dive into the research topics of 'Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan'. Together they form a unique fingerprint.

Cite this